Long-term management of patients taking immunosuppressive drugs

Australian Prescriber

Volumn 32, Issue 3, 2009, Pages 68-71

  Hsu, Denise C ^a   Katelaris, Constance H ^b  

^a Department of Geriatric Medicine   (Australia)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

Calcineurin inhibitors; Corticosteroids; Methotrexate

Indexed keywords

ALLOPURINOL; ANTIFUNGAL AGENT; ATORVASTATIN; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN INHIBITOR; CALCIUM; COLCHICINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; FOLIC ACID; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; SIMVASTATIN; SULFAMETHOXAZOLE; SULFONAMIDE; TACROLIMUS; TRIMETHOPRIM; UNINDEXED DRUG; VITAMIN D;

AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CANCER RISK; CARDIOVASCULAR RISK; CATARACT; CYTOPENIA; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; FRACTURE; GLUCOSE INTOLERANCE; GRAFT REJECTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTRAOCULAR PRESSURE; LEUKOPENIA; LIVER FUNCTION; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; LUNG TOXICITY; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; OSSIFICATION; OSTEOLYSIS; PATIENT MONITORING; PRACTICE GUIDELINE; RETINOPATHY; RISK REDUCTION; SHORT SURVEY; SIDE EFFECT; TUBULAR DYSFUNCTION; UNSPECIFIED SIDE EFFECT;

EID: 66749140291     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2009.035     Document Type: Short Survey

References (7)

1. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-784
2. Chakravarty K, McDonald H, Pullar T, Taggart A, Chalmers R, Oliver S, et al; British Society for Rheumatology, British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group; British Association of Dermatologists. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 2008;47:924-925
3. Romas E. Corticosteroid-induced osteoporosis and fractures. Aust Prescr 2008;31:45-49
4. Bone and Tooth Society, National Osteoporosis Society, National Osteoporosis Society (Great Britain), Royal College of Physicians of London. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment. London: Royal College of Physicians; 2003.
5. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-770 (Pubitemid 39524914)
6. American College of Rheumatology. Screening for hydroxychloroquine retinopathy. 2006. www.rheumatology.org/publications/position/hydroxyp2.asp [cited 2009 May 5]
7. TPMT testing before azathioprine therapy? Drug Ther Bull 2009;47:9-12.